Stratification by sex and apoe genotype identifies metabolic heterogeneity in alzheimer's disease
AssigneeDuke University
InventorsGabi Kastenmüller, Rima F. Kaddurah-Daouk, Matthias Arnold
Life of this patent
Estimating the term…
Abstract
Described herein are methods for stratifying Alzheimer's disease among male and female subjects by analyzing biomarker metabolites. In one aspect, the biomarker metabolite comprises one or more of PC ae C44:4, PC ac C44:5, or PA ae C44:6; or PC ac C44:4, PC ac C44:5, PC aa C32:1, PC aa C32:0, or PC ae C42:4.
Claims20
A method for stratifying Alzheimer's disease among male and female subjects, the method comprising:
- determining in a sample from the subject the level of at least one biomarker metabolite selected from the group consisting of PC ae C44:4, PC ae C44:5, PA ae C44:6, PC aa C32:1, PC aa C32:0, and PC ae C42:4;
- and
- diagnosing the subject as having Alzheimer's disease or an increased risk of Alzheimer's disease when the level of the at least one biomarker metabolite in the sample from the subject is different from or greater than the level in a control.
The method of claim 2, wherein the biomarker metabolites are selected from PC ae C44:4, PC ae C44:5, and PA ae C44:6.
A method of diagnosing or detecting Alzheimer's disease in a male subject, the method comprising:
- determining in a sample from the subject the level of at least one biomarker metabolite selected from the group consisting of PC ae C32:1, threonine, PC ae C36:1, PC ae C36:2, asparagine, glycine, one hydroxy-SM (SM (OH) C16:1), PC ae C40:2, and C16:1;
- and
- diagnosing the subject as having Alzheimer's disease or an increased risk of Alzheimer's disease when the level of the at least one biomarker metabolite in the sample from the subject is different from or greater than the level in a control.
A method of diagnosing or detecting Alzheimer's disease in a female subject, the method comprising:
- determining in a sample from the subject the level of at least one biomarker metabolite selected from the group consisting of C5-DC (C6-OH), C8, C10, C2, valine, proline, and histidine;
- and
- diagnosing the subject as having Alzheimer's disease or an increased risk of Alzheimer's disease when the level of the at least one biomarker metabolite in the sample from the subject is different from or greater than the level in a control.
A method of diagnosing or detecting Alzheimer's disease in an APOE ε4 carrier subject, the method comprising:
- determining in a sample from the subject the level of at least one biomarker metabolite selected from the group consisting of PC ae C44:6, PC ae C44:4, PC ae C44:5, and PC ae C42:4;
- and
- diagnosing the subject as having Alzheimer's disease or an increased risk of Alzheimer's disease when the level of the at least one biomarker metabolite in the sample from the subject is different from or greater than the level in a control.
A method of diagnosing or detecting Alzheimer's disease in an APOE ε4 non-carrier subject, the method comprising:
- determining in a sample from the subject the level of the biomarker metabolite C10;
- and
- diagnosing the subject as having Alzheimer's disease or an increased risk of Alzheimer's disease when the level of the biomarker metabolite in the sample from the subject is different from or greater than the level in a control.
A method of diagnosing or detecting Alzheimer's disease in a female APOE ε4 carrier subject, the method comprising:
- determining in a sample from the subject the level of at least one biomarker metabolite selected from PC ae C42:4, PC ae C44:5, PC ae C44:6, C10, and proline;
- and
- diagnosing the subject as having Alzheimer's disease or an increased risk of Alzheimer's disease when the level of the at least one biomarker metabolite in the sample from the subject is different from or greater than the level in a control.
Dependencies are inferred from the claim text.